Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
4519 On Other Exchanges
4519 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

chugai pharmaceutical co ltd (4519) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHUGAI PHARMACEUTICAL CO LTD (4519)

Related News

No related news articles were found.

chugai pharmaceutical co ltd (4519) Related Businessweek News

No Related Businessweek News Found

chugai pharmaceutical co ltd (4519) Details

Chugai Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceutical products in Japan and internationally. Its products in oncology include Avastin, Herceptin, Rituxan, Xeloda, Tarceva, Neutrogin, Perjeta, Kadcyla, and Alecensa; bone and joint disease products comprise Actemra, Suvenyl, Edirol, Alfarol, and Bonviva; renal disease products consist of Mircera, Oxarol, and Epogin; and other products, such as Tamiflu, Sigmart, CellCept, Pegasys, and Copegus. The company has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, central nervous system, and other diseases. Chugai Pharmaceutical Co., Ltd. has a strategic alliance with Roche; co-development agreement with Taisho Pharmaceutical Co., Ltd.; and license agreement and collaboration with Athersys, Inc. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

7,023 Employees
Last Reported Date: 04/1/15
Founded in 1925

chugai pharmaceutical co ltd (4519) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥266.0M
President, Chief Operating Officer and Repres...
Total Annual Compensation: ¥74.0M
Compensation as of Fiscal Year 2013.

chugai pharmaceutical co ltd (4519) Key Developments

Chugai Pharmaceutical Co. Ltd., Board Meeting, Apr 22, 2015

Chugai Pharmaceutical Co. Ltd., Board Meeting, Apr 22, 2015. Agenda: To amend basic policies concerning internal controls.

Chugai Pharmaceutical Co. Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Consolidated Earnings Guidance for the Year Ending December 31, 2015

Chugai Pharmaceutical Co. Ltd. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported core and IFRS revenues of JPY 117,083 million compared to JPY 124,045 million a year ago. Operating profit was JPY 20,750 million compared to JPY 31,089 million a year ago. Profit before taxes was JPY 21,174 million compared to JPY 31,263 million a year ago. Net income was JPY 14,819 million compared to JPY 19,080 million a year ago. Net income attributable to the shareholders was JPY 14,582 million compared to JPY 18,776 million a year ago. Diluted net income per share was JPY 26.68 compared to JPY 34.41 a year ago. Core operating profit was JPY 27.54 per share. Core operating profit was JPY 21.5 billion against JPY 31.4 billion last year, a decrease of 31.5% year on year. Core net income was JPY 15.3 billion against JPY 19.3 billion last year, a decrease of 20.7% year on year, due to the improvements in other financial income (expense) and the reduction of the tax burden ratio due mainly to the changes in the taxation system. Cash flows from operating activities were JPY 33.3 billion compared to JPY 15.4 billion last year. Free cash flows were JPY 10.8 billion against negative free cash flows of JPY 3.6 billion last year. Purchase of property, plant and equipment was JPY 5.1 billion against JPY 5.6 billion last year. Purchase of intangible assets was JPY 2.1 billion against JPY 721 million last year. Ratio of net income to equity attributable to Chugai shareholders (ROE) was 2.5% against 3.3% last year. Ratio of profit before taxes to total assets (ROA) was 2.9% against 4.5% last year. Core return on net operating assets (core RONOA) was 4.5% against 5.8% last year. Core profit before taxes was JPY 21.9 billion compared to JPY 31.6 billion a year ago. Core net income attributable to the shareholders was JPY 15.1 billion against JPY 19.0 billion last year. Core earnings per diluted share were JPY 27.54 against JPY 34.82 last year. On consolidated basis, the company reaffirmed earnings guidance for the year ending December 31, 2015. The company expects revenues of JPY 486,500 million, core operating profit of JPY 85,000 million and core earnings per share of JPY 104.42. The company expecting 5.5% growth in sales compared to the previous year. The company forecasting JPY 0.7 billion sales for the remaining 9 months this year.

Chugai Pharmaceutical Co. Ltd., Q1 2015 Earnings Call, Apr 22, 2015

Chugai Pharmaceutical Co. Ltd., Q1 2015 Earnings Call, Apr 22, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4519:JP ¥3,825.00 JPY -50.00

4519 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.62 USD -0.31
Eli Lilly & Co $77.95 USD -1.05
Hospira Inc $88.50 USD +0.08
Merck KGaA €95.50 EUR -2.53
Teva Pharmaceutical Industries Ltd $60.58 USD +0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation 4519 Industry Range
Price/Earnings 43.6x
Price/Sales 4.5x
Price/Book 3.4x
Price/Cash Flow 44.6x
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at